CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls

Parkinsonism and Related Disorders

Volumn 20, Issue 1, 2014, Pages 112-115

  Herbert, Megan K ^a,b   Eeftens, Jorine M ^b   Aerts, Marjolein B ^a   Esselink, Rianne A J ^a   Bloem, Bastiaan R ^a   Kuiperij, H Bea ^a,b   Verbeek, Marcel M ^a,b  

^a RADBOUD UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Cerebrospinal fluid; DJ 1; Multiple system atrophy; Parkinson's disease

Indexed keywords

BIOLOGICAL MARKER; DJ 1 PROTEIN; TAU PROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN CEREBROSPINAL FLUID LEVEL; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME;

BIOMARKERS; CEREBROSPINAL FLUID; DJ-1; MULTIPLE SYSTEM ATROPHY; PARKINSON'S DISEASE;

BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; ONCOGENE PROTEINS; PARKINSON DISEASE; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 84892831517     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2013.09.003     Document Type: Article

References (34)

1. Stefanova N., Bücke P., Duerr S., Wenning G.K. Multiple system atrophy: an update. Lancet Neurol 2009, 8:1172-1178.
2. Wenning G.K., Geser F., Krismer F., Seppi K., Duerr S., Boesch S., et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013, 12:264-274.
3. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 1998, 95:6469-6473.
4. Dickson D.W., Braak H., Duda J.E., Duyckaerts C., Gasser T., Halliday G.M., et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009, 8:1150-1157.
5. Aerts M.B., Esselink R.A.J., Abdo W.F., Bloem B.R., Verbeek M.M. CSF α-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 2012, 33. 430.e1-e3.
6. Shi M., Bradner J., Hancock A.M., Chung K.A., Quinn J.F., Peskind E.R., et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011, 69:570-580.
7. Wang Y., Shi M., Chung K.A., Zabetian C.P., Leverenz J.B., Berg D., et al. Phosphorylated alpha-synuclein in Parkinson's disease. Sci Transl Med 2012, 4. 121ra20.
8. Foulds P.G., Yokota O., Thurston A., Davidson Y., Ahmed Z., Holton J., et al. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and dementia with Lewy bodies. Neurobiol Dis 2012, 45:188-195.
9. Lei P., Ayton S., Finkelstein D.I., Adlard P.A., Masters C.L., Bush A.I. Tau protein: relevance to Parkinson's disease. Int J Biochem Cell Biol 2010, 42:1775-1778.
10. Martin E.R., Scott W.K., Nance M.A., Watts R.L., Hubble J.P., Koller W.C., et al. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA 2001, 286:2245-2250.
11. Scott W.K., Nance M.A., Watts R.L., Hubble J.P., Koller W.C., Lyons K., et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA 2001, 286:2239-2244.
12. Duka T., Duka V., Joyce J.N., Sidhu A. α-Synuclein contributes to GSK-3β-catalyzed tau phosphorylation in Parkinson's disease models. FASEB J 2009, 23:2820-2830.
13. Giasson B., Mabon M., Duda J., Montine T., Robertson D., Hurtig H., et al. Tau and 14-3-3 in glial cytoplasmic inclusions of multiple system atrophy. Acta Neuropathol 2003, 106:243-250.
14. Zhou W., Zhu M., Wilson M.A., Petsko G.A., Fink A.L. The oxidation state of DJ-1 regulates its chaperone activity toward α-synuclein. JMol Biol 2006, 356:1036-1048.
15. Batelli S., Albani D., Rametta R., Polito L., Prato F., Pesaresi M., et al. DJ-1 modulates α-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70. PLoS ONE 2008, 3:e1884.
16. Kilarski L.L., Pearson J.P., Newsway V., Majounie E., Knipe M.D.W., Misbahuddin A., et al. Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. Mov Disord 2012, 27:1522-1529.
17. Johnson G.V.W., Stoothoff W.H. Tau phosphorylation in neuronal cell function and dysfunction. JCell Sci 2004, 117:5721-5729.
18. Ishizawa T.M., Mattila P.M.D.P., Davies P.P., Wang D.M., Dickson D.W.M. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. JNeuropathol Exp Neurol 2003, 62:389-397.
19. Neumann M., Müller V., Görner K., Kretzschmar H., Haass C., Kahle P. Pathological properties of the Parkinson's disease-associated protein DJ-1 in α-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease. Acta Neuropathol 2004, 107:489-496.
20. Hong Z., Shi M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010, 133:713-726.
21. Waragai M., Wei J., Fujita M., Nakai M., Ho G.J., Masliah E., et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun 2006, 345:967-972.
22. Salvesen L., Bech S., Lokkegaard A., Hjermind L.E., Nielsen J.E., Pakkenberg B., et al. The DJ-1 concentration in cerebrospinal fluid does not differentiate among parkinsonian syndromes. Parkinsonism Relat Disord 2012, 18:899-901.
23. Bandopadhyay R., Kingsbury A.E., Cookson M.R., Reid A.R., Evans I.M., Hope A.D., et al. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 2004, 127:420-430.
24. Abdo W.F., Bloem B.R., Van Geel W.J., Esselink R.A.J., Verbeek M.M. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol Aging 2007, 28:742-747.
25. Montine T.J., Shi M., Quinn J.F., Peskind E.R., Craft S., Ginghina C., et al. CSF Aβ42 and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010, 25:2682-2685.
26. Mollenhauer B., Trenkwalder C. Neurochemical biomarkers in the differential diagnosis of movement disorders. Mov Disord 2009, 24:1411-1426.
27. Alves G., Brønnick K., Aarsland D., Blennow K., Zetterberg H., Ballard C., et al. CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. JNeurol Neurosurg Psychiatry 2010, 81:1080-1086.
28. van Dijk K.D., Bidinosti M., Weiss A., Raijmakers P., Berendse H.W., van de Berg W.D.J. Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity. Eur J Neurol 2013, 10.1111/ene.12176.
29. Mollenhauer B., Trautmann E., Taylor P., Manninger P., Sixel-Döring F., Ebentheuer J., et al. Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett 2013, 532:44-48.
30. Wennström M., Surova Y., Hall S., Nilsson C., Minthon L., Boström F., et al. Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE 2013, 8:e53250.
31. Tateno F., Sakakibara R., Kawai T., Kishi M., Murano T. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with Lewy bodies, multiple system atrophy). Alzheimer Dis Assoc Disord 2012, 26:213-216.
32. Hall S., Öhrfelt A., Constantinescu R., Andreasson U., Surova Y., Bostrom F., et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012, 69:1445-1452.
33. Mollenhauer B., Locascio J.J., Schulz-Schaeffer W., Sixel-Döring F., Trenkwalder C., Schlossmacher M.G. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011, 10:230-240.
34. Litvan I., Goetz C.G., Jankovic J., Wenning G.K., Booth V., Bartko J.J., et al. What is the accuracy of the clinical diagnosis of multiple system atrophy?: a clinicopathologic study. Arch Neurol 1997, 54:937-944.